Locking an α-helix in place with an all-hydrocarbon or lactam staple (i,i+4 / i,i+7 spacing) to resist proteolysis and restore binding to intracellular targets like p53/MDM2
Every stapled peptide program begins with a helical wheel projection of the target sequence — typically an 8- to 22-residue fragment of a natural protein-protein interaction helix such as the p53 transactivation domain (residues 17–29, sequence LSQETFSDLWKLL) or a BH3 domain from a BCL-2 family apoptosis regulator. The goal is to identify two or three positions on the solvent-exposed, non-interacting face of the helix — the face pointing away from the target groove — where the native side chain can be swapped for an olefin-bearing non-natural amino acid without disturbing the residues that actually contact the binding partner.
The stapling strategy pioneered by Schafmeister, Verdine, and later refined extensively by the Walensky and Verdine laboratories relies on α,α-disubstituted amino acids bearing a pendant olefin tail of defined length and stereochemistry:
Core building blocks: • (S)-2-(4′-pentenyl)alanine (S5): 5-carbon olefin tail, S configuration at Cα • (R)-2-(7′-octenyl)alanine (R8): 8-carbon olefin tail, R configuration at Cα • Both retain a quaternary, α-methylated Cα center — this pre-organizes local backbone (φ,ψ) angles toward helical values (φ≈-60°, ψ≈-45°) even before ring closure, and blocks epimerization during solid-phase coupling
Spacing rules and macrocycle geometry: • i, i+7 (S5...R8): spans two complete turns of the helix (3.6 residues/turn × ~1.5 Å rise = ~10.5 Å); after RCM, forms an 8-carbon-chain macrocycle that is close to ideal for stabilizing a full helical turn pair — this is the most widely used and best-validated spacing (used in ATSP-7041, ALRN-6924) • i, i+4 (S5...S5): single-turn staple; shorter, more rigid; useful for very short helices or when double-stapling (i,i+4,i+7 “stitching”) for extra rigidity • i, i+11: three-turn span for long recognition helices; requires longer olefin tails
Position selection workflow: 1. Generate a helical wheel (18°/residue) or Edmundson wheel projection of the target sequence 2. Identify the binding face by mutagenesis data, alanine scanning, or a co-crystal structure with the natural partner (e.g., p53 helix bound in the MDM2 hydrophobic cleft, PDB 1YCR) 3. Mark residues on the opposite (solvent) face as staple-eligible; avoid replacing residues that form salt bridges or hydrogen bonds critical for affinity 4. Confirm eligible positions are not proline (helix breaker) or glycine (helix destabilizer) in the native sequence 5. Select two positions separated by exactly i,i+4 or i,i+7 on the solvent face
Worked example — SAH-p53-8 (an early Walensky-lab p53 stapled peptide): Native p53(17–29): LSQETFSDLWKLL — residues Phe19, Trp23, Leu26 form the critical MDM2-binding triad. Staple positions were placed at residues 21 and 28 (i,i+7), well clear of the binding triad, preserving nanomolar affinity while adding the mechanical brace.
With the olefin-bearing residues incorporated at the chosen positions, the peptide is assembled by standard Fmoc solid-phase peptide synthesis (SPPS) on Rink amide resin, and the macrocyclic hydrocarbon staple is forged directly on-resin using ruthenium-catalyzed ring-closing metathesis (RCM). This single carbon-carbon bond-forming step converts a flexible, largely unstructured linear peptide into a covalently braced, conformationally constrained helix — the defining chemical transformation of the entire technology.
Synthetic sequence for a hydrocarbon-stapled peptide:
1. Fmoc-SPPS chain assembly: • Rink amide MBHA resin (0.3–0.6 mmol/g loading) • Standard couplings: Fmoc-amino acid / HATU / DIPEA in DMF, 2× 45 min • At the two designated positions, Fmoc-S5-OH and Fmoc-R8-OH replace the native residue — coupling is slower (steric bulk of quaternary Cα) and typically requires extended coupling times (4–12 h) or double coupling
2. On-resin ring-closing metathesis: • Resin swollen in degassed 1,2-dichloroethane (DCE) • Grubbs 1st-generation catalyst (benzylidene-bis(tricyclohexylphosphine)dichlororuthenium), 20 mol%, added in DCE • Reaction: 2× 2-hour treatments at room temperature to 40°C, resin agitated under inert atmosphere • Mechanism: Ru-carbene undergoes [2+2] cycloaddition with each terminal olefin sequentially, forming a metallacyclobutane intermediate that retro-[2+2]s to release ethylene gas and form the new internal C=C bond, closing the macrocycle across the i to i+7 span • Loss of gaseous ethylene is thermodynamically favorable and drives the ring-closure equilibrium to completion; both E and Z alkene isomers can form, with the peptide typically purified to isolate the more helix-stabilizing isomer
3. Cleavage and global deprotection: • TFA/triisopropylsilane/water (95:2.5:2.5), 2–3 h, cleaves peptide from resin and removes acid-labile side-chain protecting groups • Crude peptide precipitated in cold ether, purified by reverse-phase HPLC (C18, water/acetonitrile + 0.1% TFA gradient) • Purity confirmed >95% by analytical HPLC; identity confirmed by ESI- or MALDI-TOF mass spectrometry (staple formation reduces MW by 28 Da relative to the bis-olefin precursor, corresponding to loss of ethylene, C2H4)
4. Why the covalent brace stabilizes helix: • The unstapled linear peptide samples a broad ensemble of backbone conformations in solution — helix formation costs conformational entropy that is rarely repaid by intramolecular hydrogen bonds alone for peptides shorter than ~20 residues • The staple pre-organizes the two flanking turns by covalently fixing the i and i+7 Cα positions at a separation matching the ideal helical geometry, sharply reducing the entropic penalty of folding • Net effect: the helix-coil equilibrium is shifted toward the folded state even in the absence of tertiary contacts, raising measured helicity from roughly 20–35% (linear) to 50–90% (stapled), depending on sequence, staple position, and number of staples
Once purified, every stapled peptide is biophysically characterized to confirm that the intended conformational stabilization actually occurred. Circular dichroism (CD) spectroscopy remains the workhorse assay: an α-helix produces a distinctive spectral signature with double minima at 208 nm and 222 nm, and the depth of these minima scales quantitatively with the fraction of the peptide population that is helical at any given moment in the fast-exchanging helix-coil equilibrium.
Quantitative helicity determination:
1. CD data acquisition: • Peptide dissolved at 20–50 µM in aqueous buffer (10 mM potassium phosphate, pH 7.4) or 50% aqueous trifluoroethanol (TFE) to probe maximal helical propensity • Far-UV CD spectrum recorded 190–260 nm, 1 mm pathlength quartz cuvette, 20°C • Mean residue ellipticity [θ] calculated: [θ]=θ_obs/(10·c·l·n), where c=molar concentration, l=pathlength (cm), n=number of residues
2. Percent helicity calculation: • Fractional helicity = [θ]222 / [θ]222,max • [θ]222,max estimated from a reference fully-helical peptide or by the Chen/Scholtz empirical formula: [θ]max = -40,000·(1 - 2.5/n) deg·cm²·dmol⁻¹, correcting for finite-length end fraying • Unstapled linear analogs of typical PPI-derived helices show 15–35% helicity in aqueous buffer; single hydrocarbon staples raise this to 50–70%; optimized double-stapled (“stitched”) peptides can exceed 90%
3. Thermal and chemical denaturation: • Thermal melt: CD signal at 222 nm monitored 4°C→95°C; Tm extracted by fitting to a two-state sigmoidal unfolding model • Unstapled helical peptides frequently show no discrete cooperative transition (they are only marginally structured to begin with); stapled peptides show clear cooperative melts with Tm often exceeding 60–70°C • Chemical denaturation with guanidinium hydrochloride (GdnHCl) or urea provides ΔG_unfold via linear extrapolation (LEM); stapled peptides typically show a 1–2 M increase in denaturant midpoint concentration (Cm) versus the linear parent
4. Orthogonal structural confirmation: • 2D NMR (TOCSY/NOESY) in aqueous or micellar solution: sequential dαN(i,i+1) and medium-range dαN(i,i+3)/dαN(i,i+4) NOEs confirm helical register; chemical shift index (CSI) of Cα protons corroborates helicity per-residue • X-ray crystallography of the stapled peptide bound to its target (e.g., ATSP-7041 in complex with MDM2, PDB 4N5T) provides atomic-resolution confirmation of both the helical backbone and the staple’s solvent-exposed positioning • Analytical ultracentrifugation and size-exclusion chromatography confirm the peptide remains monomeric (stapling should not induce aggregation)
The prototype dual MDM2/MDMX inhibitor ATSP-7041 (a stitched, doubly-stapled 12-mer derived from the p53 helix) showed 85% helical content by CD versus 12% for the unmodified p53(17–29) peptide, and its 1.7 Å co-crystal structure with MDM2 (PDB 4N5T) confirmed that the two hydrocarbon staples project cleanly away from the binding interface without perturbing the docked orientation of the critical Phe19/Trp23/Leu26 triad.
A helix that is merely stable in a cuvette is not yet a drug. Unmodified peptides are typically degraded within minutes by serum and tissue proteases and cannot cross the plasma membrane to reach intracellular targets like MDM2. Two properties must be engineered simultaneously by the staple: resistance to proteolytic cleavage, and sufficient membrane permeability for productive intracellular delivery without relying on active transporters.
Why stapling confers proteolytic resistance:
1. Conformational shielding: • Most proteases (trypsin, chymotrypsin, pepsin, and serum exopeptidases/endopeptidases) require the substrate backbone to adopt an extended, largely unfolded conformation to insert into the enzyme active-site cleft • A rigid, pre-folded α-helix denies this extended presentation — the scissile amide bonds are held in a helical (φ,ψ) geometry incompatible with productive binding in most protease active sites • The quaternary, α-methylated Cα centers of the staple residues themselves are also sterically resistant to any residual protease engagement near the staple
2. Standard stability assays: • In vitro protease challenge: peptide (10–50 µM) incubated with trypsin or chymotrypsin (1:50–1:100 enzyme:substrate) in PBS, 37°C; aliquots quenched at timepoints (0, 5, 15, 30, 60, 120 min) and quantified by LC-MS/MS or analytical HPLC; t½ extracted from single-exponential decay fit • Human/mouse serum stability: peptide incubated in 50–100% serum at 37°C up to 24–48 h; intact peptide quantified by LC-MS/MS with an internal standard; unstapled linear controls are frequently >90% degraded by 30–60 min under identical conditions, while stapled analogs routinely retain >80% intact peptide at 24 h
3. Cell penetration mechanisms and assays: • The hydrocarbon staple substantially increases peptide lipophilicity (calculated logP increases 1–3 units depending on staple length and number), promoting direct translocation across the lipid bilayer rather than strict dependence on endocytosis • Uptake is measured by flow cytometry or confocal microscopy using N-terminally FITC- or TAMRA-labeled peptide, incubated with live cells (e.g., HCT116, SJSA-1) for 1–4 h, followed by trypan blue or trypsinization to remove/quench surface-bound (non-internalized) signal • Mechanistic studies (energy-depletion controls at 4°C, pinocytosis inhibitors, macropinocytosis markers) indicate stapled peptides use a mix of direct penetration and macropinocytosis-like endocytic uptake, with subsequent endosomal escape being a key optimization parameter distinguishing productive intracellular delivery from endosomal sequestration • Uptake efficiency correlates positively with staple hydrophobicity and net positive charge but must be balanced against hemolysis/cytotoxicity liabilities from amphipathic, membrane-lytic character at high lipophilicity
The ultimate test of a stapled peptide is whether the pre-organized helix engages its intended intracellular target with high affinity and translates that engagement into a measurable cellular and organismal pharmacologic effect. For p53-reactivating stapled peptides, this means binding the p53-binding groove of MDM2 and/or MDMX, displacing the tumor suppressor from its inhibitory complex, and restoring p53-driven apoptosis in cancer cells that retain wild-type p53.
Biophysical and cellular validation pipeline:
1. Direct binding assays: • Fluorescence polarization (FP) competition assay: a fluorescein-labeled tracer peptide pre-bound to recombinant MDM2 or MDMX; test peptide titrated in; loss of polarization signal as tracer is displaced yields IC50, converted to Ki via the Cheng-Prusoff-like Nikolovska-Coleska equation • Isothermal titration calorimetry (ITC): label-free, provides Kd, stoichiometry (n≈1), ΔH, and ΔS directly — stapled peptides typically show favorable (exothermic) binding enthalpy consistent with a pre-paid conformational entropy cost from stapling, versus linear peptides that pay a larger entropic penalty upon target-induced folding • Surface plasmon resonance (SPR): immobilized MDM2/MDMX, peptide flowed at a concentration series, yields on/off rates (ka, kd) and Kd = kd/ka; stapled peptides generally show slower off-rates than linear analogs due to reduced conformational sampling in the bound state
2. Cell-based pharmacodynamics: • p53 stabilization: Western blot or ELISA for total and phosphorylated p53 protein levels after peptide treatment (p53 is normally kept at low steady-state levels by MDM2-mediated ubiquitination and proteasomal degradation; disrupting this interaction stabilizes p53) • Downstream transcriptional targets: p21 (CDKN1A), MDM2 itself (negative feedback loop), and PUMA induction measured by qPCR/Western blot confirm functional p53 transcriptional reactivation • Cell viability/apoptosis: CellTiter-Glo or Annexin V/PI flow cytometry comparing p53 wild-type (e.g., SJSA-1, HCT116) versus p53-null/mutant isogenic controls — selective killing of wild-type p53 lines demonstrates on-mechanism activity and rules out generic peptide cytotoxicity
3. In vivo pharmacology: • Pharmacokinetics: intravenous or subcutaneous dosing in mice; plasma concentration-time profile by LC-MS/MS; stapled peptides show markedly improved half-life versus linear controls due to combined proteolytic resistance and reduced renal clearance at optimized size/charge • Efficacy: xenograft tumor models (e.g., SJSA-1 osteosarcoma, subcutaneous flank implantation) dosed with stapled peptide versus vehicle; tumor volume tracked over 2–4 weeks; significant growth inhibition or regression at well-tolerated doses supports therapeutic index • Clinical translation: ALRN-6924, a stapled dual MDM2/MDMX inhibitor derived directly from this class, entered clinical trials for p53 wild-type acute myeloid leukemia/myelodysplastic syndrome and solid tumors, and has additionally been explored as a chemoprotective agent that transiently arrests p53-wild-type normal tissue to shield it from chemotherapy toxicity — an unusual dual-use pharmacology enabled directly by the mechanism of MDM2/MDMX blockade.
In the original 2013 PNAS report (Chang et al.), the stitched peptide ATSP-7041 bound MDM2 with Kd=0.9 nM and MDMX with Kd=6 nM — roughly 1,000-fold tighter than the corresponding unstapled linear p53 peptide — and produced dose-dependent regression of SJSA-1 xenograft tumors in mice at 30 mg/kg administered intravenously three times per week, with no signs of overt toxicity, establishing hydrocarbon stapling as a clinically credible route to drugging classically "undruggable" intracellular protein-protein interactions.